Back to results
US 2011/0300100 A1Published application
Il-11 muteins
AssigneeCSL Limited
InventorManuel BACA
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to the treatment of an interleukin-11 (IL-11)-mediated condition. More particularly, the present invention provides the use of modified forms of IL-11 which modulate IL-11 signaling in the treatment of IL-11-mediated conditions.
Claims15
A human IL-11 mutein comprising:
- (i) an amino acid sequence with at least 85% identity to amino acids 10 to 175 of SEQ ED NO:5;
- (ii) the amino acid sequence PAIDY replacing the amino acid sequence AMSAG at amino acid positions 58 to 62 of human IL-11;
- and
- (iii) at least one other amino acid substitution, addition or deletion between amino acids 10 to 175 of SEQ ID NO:5 which is in addition to a substitution mutation from tryptophan (W) at amino acid position 147 of human IL-11 to alanine (A) or cysteine (C);
- wherein the mutein does not have the amino acid sequence set forth in amino acids 10 to 175 of SEQ ID NO:5 or SEQ ID NO:9 or SEQ ID NO:11.
2 more elements
Dependencies are inferred from the claim text.